rs113488022
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Targeted genotyping revealed BRAF p.Val600Glu in 95% of papillary craniopharyngiomas (36 of 39 tumors) and mutation of CTNNB1 in 96% of adamantinomatous craniopharyngiomas (51 of 53 tumors).
|
24413733 |
2014 |
rs113488022
|
|
|
0.050 |
GeneticVariation |
BEFREE |
BRAF V600E mutant papillary tumors represent a clearly distinct clinical-pathological entity of craniopharyngiomas.
|
30187175 |
2018 |
rs113488022
|
|
|
0.050 |
GeneticVariation |
BEFREE |
BRAF V600E mutations were solely found in the papCP subgroup and were not detectable in adaCP samples.
|
26927026 |
2016 |
rs113488022
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Here, we describe our treatment of a man age 39 years with multiply recurrent BRAF V600E craniopharyngioma using dabrafenib (150mg, orally twice daily) and trametinib (2mg, orally twice daily).
|
26498373 |
2016 |
rs113488022
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Recent insight in molecular pathogenesis of CP opens new perspectives on targeted therapy in papillary CP harboring BRAF-V600E mutations.
|
31678973 |
2019 |
rs121913377
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Recent insight in molecular pathogenesis of CP opens new perspectives on targeted therapy in papillary CP harboring BRAF-V600E mutations.
|
31678973 |
2019 |
rs121913377
|
|
|
0.050 |
GeneticVariation |
BEFREE |
BRAF V600E mutant papillary tumors represent a clearly distinct clinical-pathological entity of craniopharyngiomas.
|
30187175 |
2018 |
rs121913377
|
|
|
0.050 |
GeneticVariation |
BEFREE |
BRAF V600E mutations were solely found in the papCP subgroup and were not detectable in adaCP samples.
|
26927026 |
2016 |
rs121913377
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Here, we describe our treatment of a man age 39 years with multiply recurrent BRAF V600E craniopharyngioma using dabrafenib (150mg, orally twice daily) and trametinib (2mg, orally twice daily).
|
26498373 |
2016 |
rs121913377
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Targeted genotyping revealed BRAF p.Val600Glu in 95% of papillary craniopharyngiomas (36 of 39 tumors) and mutation of CTNNB1 in 96% of adamantinomatous craniopharyngiomas (51 of 53 tumors).
|
24413733 |
2014 |
rs121913399
|
|
|
0.710 |
GeneticVariation |
BEFREE |
These included 5 different point mutations, 3 of them identified in 2 different tumors: S23N (cribriform trichoblastoma), D32Y (pilomatricoma and craniopharyngioma), G34R (pilomatrical carcinoma and craniopharyngioma), S37F (2 BCCs with shadow cell differentiation), and G34V (craniopharyngioma).
|
19384065 |
2009 |
rs121913403
|
|
|
0.010 |
GeneticVariation |
BEFREE |
These included 5 different point mutations, 3 of them identified in 2 different tumors: S23N (cribriform trichoblastoma), D32Y (pilomatricoma and craniopharyngioma), G34R (pilomatrical carcinoma and craniopharyngioma), S37F (2 BCCs with shadow cell differentiation), and G34V (craniopharyngioma).
|
19384065 |
2009 |
rs28931588
|
|
|
0.710 |
GeneticVariation |
BEFREE |
These included 5 different point mutations, 3 of them identified in 2 different tumors: S23N (cribriform trichoblastoma), D32Y (pilomatricoma and craniopharyngioma), G34R (pilomatrical carcinoma and craniopharyngioma), S37F (2 BCCs with shadow cell differentiation), and G34V (craniopharyngioma).
|
19384065 |
2009 |
rs28931589
|
|
|
0.710 |
GeneticVariation |
BEFREE |
These included 5 different point mutations, 3 of them identified in 2 different tumors: S23N (cribriform trichoblastoma), D32Y (pilomatricoma and craniopharyngioma), G34R (pilomatrical carcinoma and craniopharyngioma), S37F (2 BCCs with shadow cell differentiation), and G34V (craniopharyngioma).
|
19384065 |
2009 |